Name	Efstathios Kastritis, MD
Current Position & Affiliation	Professor of Clinical Therapeutics – Medical Oncology National and Kapodistrian University of Athens School of Medicine
Country	Greece
Major Field	Amyloidosis, Plasma Cell malignancies and Monoclonal Gammopathies of Clinical Significance, Lymphoma,

Educational Background

Efstathios Kastritis, MD is Professor of Clinical Therapeutics/Internal and Medicine and Medical Oncology at the National and Kapodistrian University of Athens (NKUOA), School of Medicine. He graduated National and Kapodistrian University of Athens School of Medicine and completed residency in Internal Medicine and fellowship in Medical Oncology at the Department of Clinical Therapeutics. He received his Doctorate from the National and Kapodistrian University of Athens and was a post-doctoral Fellow at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute.

Professional Experience

Professor of Clinical Therapeutics Medical Oncology in the National and Kapodistrian University of Athens, Greece. Main research focus is Clinical and translational research in plasma cell malignancies and related disorders. I have been working for the identification of prognostic factors related to the outcomes of patients with myeloma, prediction prognosis and management of myeloma related complications and treatment-related complications and in the understanding of the biology of the disease, especially in special populations. A special focus has been the translation and clinical research in patients with asymptomatic monoclonal gammopathies (MGUS and smoldering myeloma) and in patient with myeloma, focusing on treatment outcomes, prognostic factors, disease biology and treatment-related complications. As a result, I have participated >100 clinical trials and led some of them as PI, with more than 250 publications in the field. I have organized and I am the Scientific Director of the Amyloidosis referral center, the only one in Greece, and I have special focus in translational research, clinical management and development of new therapies in AL amyloidosis. My work has resulted in the development and approval of new therapies for this disease. In this context I have led and continued to lead several phase 1, 2 and 3 clinical trials and collaborative efforts with more than 100 publications. I have done clinical and research translational research on monoclonal gammopathies associated with renal disease (MGRS) and Monoclonal Gammopathies of Clinical Significance (MGCS). Finally, I have done extensive research in the field of Waldenström's macroglobulinemia, a unique lymphoma characterized by IgM production, focusing in clinical outcomes prognostic factors and new therapies as well as translational research aiming to provide non-interventional diagnosis, prognosis and elucidation of resistance mechanisms. For all these conditions I have worked systematically to build and maintain databases and a large biobank.

Main Scientific Publications

Professor Efstathios Kastritis has published more than 520 papers in peer reviewed journals. Scopus H-index: **72** , Google Scholar H-Index : **86**

Complete List of Published Work in MyBibliography:
https://www.ncbi.nlm.nih.gov/myncbi/1Vea6ZGQTEuk7/bibliography/public/

Some recent publications in high impact journals

1. Sklavenitis-Pistofidis R, Konishi Y, Heilpern-Mallory D, Wu T, Tsakmaklis N, Aranha MP, Hunter ZR, Ali AK, Tsuji J, Haradhvala NJ, Lightbody ED, Towle K, Hevenor L, Romee R, Briercheck EL, Smith EL, Liacos CI, Kastritis E, Dimopoulos MA, Treon SP, Getz G, Ghobrial IM. Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's Macroglobulinemia. Nat Commun. 2025;16(1):1480.
2. Bagratuni TD, Theologi O, Vlachos CD, Kollias I, Maclachlan KH, Aktypi F, Mavrianou-Koutsoukou N, Liacos CI, Taouxi K, Papadimou A, Chrisostomidou K, Sakkou M, Solia I, Theodorakou F, Favrin G, Gavriatopoulou M, Terpos E, Varettoni M, Hunter ZR, Treon SP, Maura F, Dimopoulos MA, Kastritis E. Genomic landscape of IgM-MGUS and patients with stable or progressive asymptomatic Waldenstrom macroglobulinemia. Blood. 2025.
3. Theodorakakou F, Fotiou D, Apostolakou F, Papassotiriou I, Spiliopoulou V, Ntanasis-Stathopoulos I, Malandrakis P, Migkou M, Kanellias N, Eleutherakis-Papaiakovou E, Psimenou E, Papanikolaou A, Gakiopoulou C, Marinaki S, Giannouli S, Gavriatopoulou M, Terpos E, Dimopoulos MA, Kastritis E. Cystatin C as Biomarker for the Evaluation of Renal Outcome in AL Amyloidosis. Am J Hematol. 2025;100(8):1305-1313.
4. Kastritis E, Solia I, Malandrakis P, Theodorakakou F, Ntanasis-Stathopoulos I, Kanellias N, Fotiou D, Migkou M, Eleutherakis-Papaiakovou E, Spiliopoulou V, Kokkali N, Papanikolaou A, Giannouli S, Gavriatopoulou M, Terpos E, Dimopoulos MA. Patterns of progression among 427 patients with smoldering myeloma diagnosed after 2014: importance of monitoring. Blood Adv. 2025;9(17):4444-4447.
5. Terpos E, Malandrakis P, Ntanasis-Stathopoulos I, Kostopoulos IV, Eleutherakis-Papaiakovou E, Kanellias N, Spiliopoulou V, Migkou M, Fotiou D, Theodorakakou F, Kastritis E, Gavriatopoulou M, Tsitsilonis OE, Dimopoulos MA. Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma. Blood. 2025;145(20):2353-2360.
6. Bagratuni T, Aktypi F, Theologi O, Sakkou M, Verrou KM, Mavrianou-Koutsoukou N, Patseas D, Liacos C, Skourti S, Papadimou A, Taouxi K, Theodorakakou F, Kollias G, Sfikakis P, Terpos E, Dimopoulos MA, Kastritis E. Single-cell analysis of MYD88(L265P) and MYD88(WT) Waldenstrom macroglobulinemia patients. Hemasphere. 2024;8(2):e27.
7. Forgeard N, Elessa D, Carpinteiro A, Belhadj K, Minnema M, Roussel M, Huart A, Javaugue V, Pascal L, Royer B, Talbot A, Gounot R, Hegenbart U, Schonland S, Karlin L, Harel S, Kastritis E, Bridoux F, Jaccard A, Arnulf B. Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series. Blood. 2024;143(8):734-737.
8. Theodorakakou F, Briasoulis A, Fotiou D, Petropoulos I, Georgiopoulos G, Lama N, Kelekis N, Repasos E, Migkou M, Stamatelopoulos K, Dimopoulos MA, Kastritis E. Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease. Hematol Oncol. 2023;41(4):725-732.
9. Palladini G, Schonland S, Merlini G, Milani P, Jaccard A, Bridoux F, Dimopoulos MA, Ravichandran S, Hegenbart U, Roeloffzen W, Cibeira MT, Agis H, Minnema MC, Bergantim R, Hajek R, Joao C, Leonidakis A, Cheliotis G, Sonneveld P, Kastritis E, Wechalekar A. The

management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. Blood Cancer J. 2023;13(1):19.
10. Wechalekar AD, Cibeira MT, Gibbs SD, Jaccard A, Kumar S, Merlini G, Palladini G, Sanchorawala V, Schonland S, Venner C, Boccadoro M, Kastritis E. Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid. 2023;30(1):3-17.
11. Kastritis E, Migkou M, Dalampira D, Gavriatopoulou M, Fotiou D, Roussou M, Kanellias N, Ntanasis-Stathopoulos I, Malandrakis P, Theodorakakou F, Sevastoudi A, Eleutherakis-Papaiakovou E, Triantafyllou T, Terpos E, Katodritou E, Dimopoulos MA. Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications. Am J Hematol. 2022;97(9):1142-1149.
12. Kastritis E, Terpos E, Dimopoulos MA. How I treat relapsed multiple myeloma. Blood. 2022;139(19):2904-2917.
13. Dispenzieri A, Kastritis E, Wechalekar AD, Schonland SO, Kim K, Sanchorawala V, Landau HJ, Kwok F, Suzuki K, Comenzo RL, Berg D, Liu G, Kumar A, Faller DV, Merlini G. A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. Leukemia. 2022;36(1):225-235.
14. Kastritis E, Laina A, Georgiopoulos G, Gavriatopoulou M, Papanagnou ED, Eleutherakis-Papaiakovou E, Fotiou D, Kanellias N, Dialoupi I, Makris N, Manios E, Migkou M, Roussou M, Kotsopoulou M, Stellos K, Terpos E, Trougakos IP, Stamatelopoulos K, Dimopoulos MA. Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study. Leukemia. 2021;35(5):1418-1427.
15. Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schonland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL, Investigators AT. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med. 2021;385(1):46-58.